Stuart Perry / Shutterstock.com
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Jatenergy released a high performing quarterly report and announcing a nine-month gross revenue to 31 March of $53.9 million.

Jatenergy is a company specialising in milk formula sales from Australia to China.

Gross revenue for the March 2019 quarter was $20.53m.

Jatenergy firmly stated the strong sales performance comes from a recent partnership with Chinese distributors HIT Crown. HIT Crown manages online medicine sales platform China Golden.

China Golden services over one million pharmaceutical companies, hospitals and consumers.

The company also announced two new sales agreements for its products. A five-year agreement with Guangzhou Niurui Trading Company has been signed.

This agreement will see Jatenergy formulas distributed into 150 Babemax maternal retail outlets.

Guangzhou will purchase 1.5 million tins of Neurio Lactoferrin milk powder. Jatenergy also signed a one-year agreement to sell through online store Bon Bon and its Wanwustore subsidiary.

The company expects to begin sales of a new milk formula for adults in May this year. Jatenergy also secured a trademark on Green Forest’s NSW sourced canola oil, to be released in May also.

Jatenergy’s ‘Golden Koala’ product range is currently selling well in the Chinese market. The company continues plans to establish a manufacturing plant in Australia.

Jatenergy rose 1.72 percent in the ASX today.

Please see the announcement attached

JAT by the numbers
More From The Market Online

The home PC changed retail stores forever. Shekel Brainweigh can do it again

Retail store automation demands tech to prevent shoplifting and give business owners peace of mind. Shekel…

This stock provides Oz’s only HIV self-test kit – and it’s bullish on the budget

Atomo Diagnostics is the only company in Australia that provides TGA-approved HIV self-test kits. It says…

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial…

Calmer Co clocks $150K in sales of its kava-based health drinks at Coles

When microcap consumer health brand stock Calmer Co stacked its products on the shelves at Coles,…